Global Health quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	1,304	1,031	+26.5%
EBITDA	287	227	+26.3%
EBITDA margin	22.0%	22.0%	0.0 pts
Profit before tax	213	208	+2.5%
Net profit	157	159	−1.1%
EPS	₹5.91	₹5.92	−0.2%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	1,304	1,159	1,121	1,099	1,031	931	943	957	861	809	833	844	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	22.2	36.7	21.8	19.7	20.5	22.9	16.0	18.2	21.9	27.4	21.9	20.8
	1,326	1,196	1,143	1,119	1,051	954	959	975	883	836	855	865
	257	216	227	227	213	191	207	204	188	177	172	174
	40.7	27.8	28.9	28.8	31.8	20.5	20.7	28.2	23.1	17.6	18.1	20.0
	−3.5	3.1	0.0	0.1	−5.8	1.6	1.9	−4.4	−1.8	−0.3	0.3	−0.8
	319	285	281	274	256	204	205	214	201	188	185	184
	26.7	26.7	21.5	17.1	13.8	15.0	16.3	16.0	18.0	18.2	17.7	20.1
	69.0	66.5	61.2	49.7	45.1	49.3	48.4	49.4	46.6	45.5	44.0	42.9
	404	384	367	338	308	289	271	286	265	248	245	254
	1,113	1,009	986	935	863	771	770	794	739	693	682	694
	287	244	217	231	227	225	238	228	186	179	212	213
	218	177	156	181	182	175	189	179	140	134	168	170
Profit
	213	187	156	184	189	183	189	181	144	143	172	171
	0.0	0.0	−36.6	16.0	19.6	−49.9	0.0	0.0	0.0	0.0	0.0	0.0
	213	187	120	200	208	133	189	181	144	143	172	171
	54.6	32.6	22.2	35.9	41.3	36.9	39.7	48.6	36.4	39.2	50.0	47.9
	1.4	13.0	2.5	5.6	7.8	−4.8	6.6	1.7	1.0	−23.5	−1.2	−2.4
	56.0	45.6	24.8	41.4	49.2	32.1	46.2	50.3	37.4	15.7	48.8	45.4
	157	142	95.0	158	159	101	143	131	106	127	124	125
	157	142	95.0	158	159	101	143	131	106	127	124	125
	−5.2	3.7	0.6	−0.9	0.2	−2.3	2.9	0.7	−2.0	−0.0	0.5	1.0
	152	145	95.7	157	159	99.1	146	132	104	127	124	126
	159	144	95.0	158	159	101	143	—	106	127	124	—
	−1.5	−2.3	0.0	−0.0	−0.0	−0.0	−0.0	—	−0.0	−0.0	−0.1	—
Per share
	₹5.91	₹5.36	₹3.54	₹5.89	₹5.92	₹3.77	₹5.32	₹4.87	₹3.96	₹4.74	₹4.61	₹4.66
	₹5.90	₹5.34	₹3.54	₹5.89	₹5.91	₹3.77	₹5.32	₹4.87	₹3.96	₹4.74	₹4.60	₹4.66
Other comprehensive income — detail
	−5.2	3.7	0.6	−0.9	0.2	−2.3	—	—	—	—	—	—
	—	—	0.8	−1.2	—	−3.0	3.8	1.0	−2.7	−0.0	0.7	1.2
	6.9	−5.2	0.2	−0.3	−0.3	−0.8	—	—	—	—	—	—
	—	—	—	—	—	—	1.0	0.3	−0.7	0.0	0.2	0.2
	—	−0.2	—	—	—	—	—	—	—	—	—	—
	−1.7	1.3	—	—	0.1	—	—	—	—	—	—	—
	154	148	95.6	158	159	99.1	146	132	104	127	124	126
	−1.5	−2.3	0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.0	−0.1	0.0
Per share — as-filed variants
	₹5.91	₹5.36	₹3.54	₹5.89	₹5.92	₹3.77	₹5.32	₹4.87	₹3.96	₹4.74	₹4.61	₹4.66
	₹5.90	₹5.34	₹3.54	₹5.89	₹5.91	₹3.77	₹5.32	₹4.87	₹3.96	₹4.74	₹4.60	₹4.66
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,010	913	865	844	792	718	714	729	652	615	642	650
	77.4%	78.7%	77.2%	76.8%	76.8%	77.1%	75.7%	76.2%	75.7%	76.0%	77.1%	77.1%
Adjusted (ex-exceptional items) — derived
	213	187	156	184	189	183	189	181	144	143	172	171
	0.0	0.0	−36.6	16.0	19.6	−49.9	0.0	0.0	0.0	0.0	0.0	0.0
	157	142	124	146	144	139	143	131	106	127	124	125
	₹5.91	₹5.36	₹4.62	₹5.42	₹5.36	₹5.18	₹5.32	₹4.87	₹3.96	₹4.74	₹4.61	₹4.66

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMAXHEALTH APOLLOHOSP FORTIS GLAXO ANTHEM AJANTPHARM IPCALAB ABBOTINDIAMcap ₹34,922 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	843.9	832.6	808.6	861.1	956.6	943.4	931.2	1,030.8	1,099.2	1,121.0	1,159.0	1,304.1
Other Income	20.8	21.9	27.4	21.9	18.2	16.0	22.9	20.5	19.7	21.8	36.7	22.2
Total Income	864.7	854.5	836.1	883.0	974.8	959.5	954.2	1,051.3	1,118.9	1,142.8	1,195.8	1,326.2
Expenses
+ Cost of Materials Consumed	174.4	172.2	176.5	187.6	204.3	206.6	191.5	213.1	226.7	226.7	215.6	257.2
+ Purchases of Stock-in-Trade	20.0	18.1	17.6	23.1	28.2	20.7	20.5	31.8	28.8	28.9	27.8	40.7
+ Changes in Inventories	-0.8	0.3	-0.3	-1.8	-4.4	1.9	1.6	-5.8	0.1	0.0	3.1	-3.5
+ Employee Benefit Expense	183.8	184.9	187.8	201.2	214.3	205.0	204.1	256.4	274.3	280.7	284.7	319.3
+ Finance Costs	20.1	17.7	18.2	18.0	16.0	16.3	15.0	13.8	17.1	21.5	26.7	26.7
+ Depreciation & Amortisation	42.9	44.0	45.5	46.6	49.4	48.4	49.3	45.1	49.7	61.2	66.5	69.0
+ Other Expenses	253.7	245.0	247.7	264.7	286.0	271.5	288.9	308.4	338.4	367.4	384.1	403.7
Total Expenses	694.1	682.2	693.0	739.4	793.7	770.4	770.8	862.7	935.1	986.4	1,008.5	1,113.0
EBITDA	212.9	212.1	179.3	186.3	228.3	237.8	224.7	227.0	230.9	217.3	243.8	286.8
EBIT	169.9	168.1	133.9	139.7	178.9	189.3	175.4	181.9	181.2	156.1	177.2	217.8
Profit
PBT before Exceptional Items	170.6	172.4	143.1	143.7	181.1	189.1	183.3	188.5	183.8	156.4	187.3	213.3
+ Exceptional Items	0.0	0.0	0.0	0.0	0.0	0.0	-49.9	19.6	16.0	-36.6	0.0	0.0
Pretax Income	170.6	172.4	143.1	143.7	181.1	189.1	133.4	208.1	199.8	119.8	187.3	213.3
+ Current Tax	47.9	50.0	39.2	36.4	48.6	39.7	36.9	41.3	35.9	22.2	32.6	54.6
+ Deferred Tax	-2.4	-1.2	-23.5	1.0	1.7	6.6	-4.8	7.8	5.6	2.5	13.0	1.4
Tax Expense	45.4	48.8	15.7	37.4	50.3	46.2	32.1	49.2	41.4	24.8	45.6	56.0
Net Income	125.2	123.5	127.3	106.3	130.8	142.9	101.4	159.0	158.4	95.0	141.7	157.3
+ Net Income — Continuing Ops	125.2	123.5	127.3	106.3	130.8	142.9	101.4	159.0	158.4	95.0	141.7	157.3
+ Other Comprehensive Income	1.0	0.5	-0.0	-2.0	0.7	2.9	-2.3	0.2	-0.9	0.6	3.7	-5.2
Total Comprehensive Income	126.1	124.1	127.3	104.2	131.6	145.7	99.1	159.2	157.5	95.7	145.4	152.1
Net Income to Common	—	123.6	127.4	106.3	—	142.9	101.4	159.0	158.4	95.0	144.0	158.7
Minority Interest	—	-0.1	-0.0	-0.0	—	-0.0	-0.0	-0.0	-0.0	0.0	-2.3	-1.5
Per Share
Basic EPS	4.66	4.61	4.74	3.96	4.87	5.32	3.77	5.92	5.89	3.54	5.36	5.91
Diluted EPS	4.66	4.60	4.74	3.96	4.87	5.32	3.77	5.91	5.89	3.54	5.34	5.90
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-2.3	0.2	-0.9	0.6	3.7	-5.2
+ Items NOT to be Reclassified to P&L	1.2	0.7	-0.0	-2.7	1.0	3.8	-3.0	—	-1.2	0.8	—	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.8	-0.3	-0.3	0.2	-5.2	6.9
+ Tax on Items NOT to be Reclassified — alt tag	0.2	0.2	0.0	-0.7	0.3	1.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	—	—	—	—	—	—	—	—	—	—	-0.2	—
+ Tax on Items to be Reclassified	—	—	—	—	—	—	—	0.1	—	—	1.3	-1.7
Comprehensive Income — Owners of Parent	126.1	124.2	127.4	104.3	131.6	145.8	99.1	159.2	157.5	95.6	147.7	153.6
Comprehensive Income — Non-controlling Interests	0.0	-0.1	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0	-0.0	0.0	-2.3	-1.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	4.66	4.61	4.74	3.96	4.87	5.32	3.77	5.92	5.89	3.54	5.36	5.91
Diluted EPS — Continuing Operations	4.66	4.60	4.74	3.96	4.87	5.32	3.77	5.91	5.89	3.54	5.34	5.90
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	650.4	641.9	614.9	652.2	728.6	714.2	717.6	791.8	843.7	865.4	912.5	1,009.7
Gross Margin %	77.06	77.10	76.04	75.74	76.17	75.71	77.06	76.81	76.75	77.19	78.73	77.43
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	170.6	172.4	143.1	143.7	181.1	189.1	183.3	188.5	183.8	156.4	187.3	213.3
− Exceptional Items (reconciliation)	0.0	0.0	0.0	0.0	0.0	0.0	-49.9	19.6	16.0	-36.6	0.0	0.0
Net Income Adj (tax-effected)	125.2	123.5	127.3	106.3	130.8	142.9	139.3	144.0	145.7	124.1	141.7	157.3
EPS Adj	4.66	4.61	4.74	3.96	4.87	5.32	5.18	5.36	5.42	4.62	5.36	5.91
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	53.7	53.7	53.7	53.7	53.7	53.7	53.7	53.8	53.8	53.8	53.7	53.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Global Health Q2 FY27 results date

Global Health (NSE: MEDANTA) will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, according to the board-meeting notice it filed on 22 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹159 crore, down 0.2% from ₹159 crore in Q1 FY26 and up 10.2% from ₹144 crore in Q4 FY26. Revenue from operations was ₹1,304 crore, up 26.5% year on year and up 12.5% from the previous quarter.

Board-meeting notice filed: 22 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 30 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 3 November 2026Tuesday · notice filed 22 Oct
Q1 FY27 net profit: ₹159 Cr−0.2% vs Q1 FY26+10.2% vs Q4 FY26
Q1 FY27 revenue: ₹1,304 Cr+26.5% vs Q1 FY26+12.5% vs Q4 FY26
Q1 FY27 operating margin: 16.7%−0.9 pts vs Q1 FY26+1.4 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹158 CrRevenue ₹1,099 Cr
Q1 FY27 EPS (basic): ₹5.91

Questions

When will Global Health announce its Q2 FY27 results?

On 3 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 22 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What were Global Health's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹159 crore, down 0.2% from ₹159 crore in Q1 FY26 and up 10.2% from ₹144 crore in Q4 FY26. Revenue from operations was ₹1,304 crore, up 26.5% year on year and up 12.5% from the previous quarter.

What was Global Health's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹556 crore in FY26 (April 2025–March 2026), up 15.6% from ₹481 crore in FY25. It was ₹478 crore in FY24 and ₹326 crore in FY23: up 70.7% over three years, 19.5% a year on average.

What will Global Health's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹158 crore and revenue from operations ₹1,099 crore. The latest quarter, Q1 FY27, had a net profit of ₹159 crore and revenue of ₹1,304 crore.

How has Global Health's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹158 crore in Q2 FY26, ₹95 crore in Q3 FY26, ₹144 crore in Q4 FY26 and ₹159 crore in Q1 FY27. That is ₹556 crore over the four quarters, up 4.1% from ₹534 crore in the four quarters before. Revenue from operations: ₹1,099 crore, ₹1,121 crore, ₹1,159 crore and ₹1,304 crore.

What was Global Health's revenue in FY26?

Revenue from operations was ₹4,410 crore in FY26 (April 2025–March 2026), up 19.4% from ₹3,692 crore in FY25. It was ₹3,275 crore in FY24 and ₹2,694 crore in FY23: up 63.7% over three years, 17.9% a year on average.

Where do these Global Health figures come from?

From Global Health's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.